Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06066359 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06066359 · ClinicalTrials.gov record · last posted 2026-08-20

Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma

StatusRecruiting
PhasePhase 1/2
Started2023-11-30
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.

Protocol amendment history 3 changes detected by DataLookout

2026-08-08
Primary completion pushed: 2026-08-31 → 2028-08-31
2026-05-14
Primary endpoint(s) modified
WasIncidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
NowIncidence of dose-limiting toxicities (Part A), Overall response rate (Part B)
2026-05-14
Trial arms changed: 4 → 1
Trial Details
NCT Number NCT06066359
Lead Sponsor M.D. Anderson Cancer Center
Conditions Relapsed/Refractory Myeloma
Enrollment 44 participants
Start Date 2023-11-30
Primary Completion 2028-08-31 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-20